CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process:
Karen Green, MD, Anne Jacobson, MPH, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of: AstraZeneca Pharmaceuticals LP; Marie Bialek, PharmD — freelancer/contractor: McNeil Consumer & Specialty Pharmaceuticals; Sally Bogert, RNC, WHCNP — shareholder of: Amgen Inc and Genentech BioOncology. Research To Practice receives educational grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, ImClone Systems, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:
Dr Kim — Consulting Fees: Genentech BioOncology, ImClone Systems, OSI Pharmaceuticals Inc, Sanofi-Aventis; Contracted Research: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Sanofi-Aventis. Dr Posner — Consulting Fees: Allos Therapeutics, Amgen Inc, BioVex, Boehringer Ingelheim GmbH, Bristol- Myers Squibb Company, DNAR Inc, GlaxoSmithKline, ImClone Systems, Millennix Oncology, OXiGENE Inc, Polaris Pharmaceuticals Inc, Promedior Inc, Sanofi-Aventis; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Millennium Pharmaceuticals Inc, OSI Pharmaceuticals Inc, Pfizer Inc, Sanofi-Aventis; Honoraria: Amgen Inc, Bristol-Myers Squibb Company, Sanofi-Aventis. Dr Curran — Consulting Fees: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Genmab, ImClone Systems, OSI Pharmaceuticals Inc.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
|
EDITOR
Neil Love, MD
INTERVIEWS
Edward S Kim, MD
- Select Publications
Marshall R Posner, MD
- Select Publications
 |
 |
 |
 |
